Brookline Capital Markets Forecasts NBP FY2026 Earnings

Key Points

• Brookline Capital Markets forecasts a FY2026 loss of $0.77 per share for Novabridge Biosciences, compared with the current-year consensus estimate of a $0.30 loss. It also projects losses through FY2030, including $1.31 per share in FY2027.
• Analyst views are mixed: one broker rates NBP a Buy and one a Sell, giving the stock an average Hold rating and a consensus price target of $9.
• NBP opened at $1.01, its 12-month low; its 12-month high is $5.19. An insider sold 107,978 shares to cover tax withholding on vested equity awards.

Novabridge Biosciences (NASDAQ:NBP - Free Report) - Research analysts at Brookline Capital Markets issued their FY2026 EPS estimates for shares of Novabridge Biosciences in a research report issued on Monday, November 2nd. Brookline Capital Markets analyst K. Raja expects that the company will post earnings per share of ($0.77) for the year. The consensus estimate for Novabridge Biosciences' current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for Novabridge Biosciences' FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($1.25) EPS, FY2029 earnings at ($1.43) EPS and FY2030 earnings at ($0.92) EPS.

Several other brokerages also recently issued reports on NBP. Weiss Ratings reiterated a "sell (d-)" rating on shares of Novabridge Biosciences in a report on Thursday, August 27th. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Novabridge Biosciences in a research note on Thursday, August 20th. Finally, Wall Street Zen upgraded Novabridge Biosciences from a "strong sell" rating to a "sell" rating in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $9.00.

Novabridge Biosciences Stock Performance

NBP stock opened at $1.01 on Thursday. Novabridge Biosciences has a twelve month low of $1.01 and a twelve month high of $5.19. The stock's 50 day moving average is $1.46 and its 200-day moving average is $2.04.

Novabridge Biosciences (NASDAQ:NBP - Get Free Report) last issued its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) EPS for the quarter.

Insider Activity

In other news, insider Sean Wuxiong Cao sold 107,978 shares of the company's stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $0.74, for a total value of $79,903.72. Following the completion of the transaction, the insider directly owned 266,467 shares of the company's stock, valued at $197,185.58. This represents a 28.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 119,469 shares of company stock valued at $88,325 over the last three months. Corporate insiders own 22.10% of the company's stock.

About Novabridge Biosciences

Novabridge Biosciences NASDAQ: NBP is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival.

The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.